The primary patent for oseltamivir phosphate, the active ingredient in Tamiflu, expired in the United States in 2016 [1][2]. However, secondary patents and exclusivities may have extended market protection for specific formulations or indications [3].
When does Tamiflu's market exclusivity end?
Market exclusivity for Tamiflu may extend beyond the primary patent expiration date due to various factors, including new patent filings for improved formulations or manufacturing processes, and regulatory exclusivities granted for new indications or pediatric studies [3]. These can create layers of protection that delay generic competition.
Can generic oseltamivir be sold now?
Generic versions of oseltamivir have entered the market in some regions following the expiration of primary patents [1][2]. The availability of generics can depend on regulatory approvals in specific countries and whether any remaining secondary patents or exclusivities prevent their launch [3].
Who makes generic oseltamivir?
Several pharmaceutical companies manufacture generic oseltamivir. These often include companies specializing in generic drug production that seek to market versions of the drug once patent protections have lapsed [1][2].
What is oseltamivir used for?
Oseltamivir is an antiviral medication used to treat and prevent influenza A and B infections in individuals aged one year and older [4]. It works by inhibiting the enzyme neuraminidase, which is essential for the release of new virus particles from infected cells [5].
How effective is oseltamivir?
Clinical studies have shown that oseltamivir can shorten the duration of influenza symptoms by about one day and reduce the risk of complications, such as pneumonia and bronchitis, when started within 48 hours of symptom onset [4].
What are the side effects of oseltamivir?
Common side effects of oseltamivir include nausea, vomiting, headache, and abdominal pain [4]. In rare cases, more serious side effects such as neuropsychiatric events (e.g., confusion, delirium, hallucinations) have been reported, particularly in children and adolescents [4][6].
What is the difference between Tamiflu and generic oseltamivir?
Tamiflu is the brand name for oseltamivir phosphate manufactured by Genentech, a member of the Roche Group [7]. Generic oseltamivir contains the same active ingredient and is expected to have the same therapeutic effect and safety profile as the brand-name drug. The primary differences typically lie in the inactive ingredients, manufacturer, and price [1][2].
Why are patents important for drugs like Tamiflu?
Patents provide a period of market exclusivity for innovative drugs, allowing pharmaceutical companies to recoup their research and development investments. This exclusivity encourages further investment in discovering and developing new medicines [3]. Once patents expire, other companies can produce and sell generic versions of the drug, which typically leads to lower prices for consumers and healthcare systems.
What are the risks associated with oseltamivir?
Beyond the known side effects, there have been post-marketing reports of neuropsychiatric events associated with oseltamivir use [6]. While a causal link is not definitively established for all cases, regulatory agencies advise caution and monitoring for such events, especially in vulnerable populations [6].
Sources:
[1] https://drugpatentwatch.com/blog/oseltamivir-patent-expiry-date
[2] https://drugpatentwatch.com/
[3] https://drugpatentwatch.com/blog/understanding-drug-exclusivity-and-market-protection
[4] https://www.nhs.uk/medicines/oseltamivir/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2800054/
[6] https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-2009-and-2010-recommendations-regarding-oseltamivir-tamiflu-and-central-nervous-system-and-behavioral-events
[7] https://www.gene.com/media/press-releases/display? PRUniqueId=15169